[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcioce6f788d":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcioce6f788d","诺华制药(NVS)神经免疫管线“悲喜交加”：患者死亡致CAR-T临床试验暂停-MS口服药后期试验告捷","\u002Fdoc\u002Fdcioce6f788d","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\n\u003C\u002Fp>\u003Cp>\u003Cspan>美股投资网获悉，诺华制药(NVS)在神经与自身免疫领域迎来“冰火两重天”公司因三名患者死亡紧急叫停八项CAR-T疗法临床试验;不过，其多发性硬化症(MS)口服药remibrutinib在后期临床试验中取得积极结果。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>CAR-T试验紧急暂停\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>诺华制药在8月底暂停了八项针对自身免疫和神经系统疾病的实验性疗法临床试验，此前有三名患者死亡。这种实验性疗法被称为嵌合抗原受体T细胞免疫疗法(CAR-T)。CAR-T疗法通过改造患者的免疫细胞，使其识别特定靶点并摧毁癌细胞。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>该瑞士制药公司发言人表示，在得知三例因严重免疫反应而死亡的病例后，公司暂时中止了相关研究。目前尚不清楚这些死亡事件发生的具体时间。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>诺华制药发言人表示，公司正在“对所观察到的安全事件进行全面审查”，并将这种致命免疫反应描述为CAR-T疗法中已知的安全风险。诺华还表示正在与监督各项暂停研究的独立安全委员会合作，并与监管机构共享已知信息。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>据报道，百时美施贵宝(BMY)出于预防性考量，已暂停其CAR-T疗法在自身免疫性疾病中的类似试验。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>MS口服药迎来突破\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>然而，诺华在另一条战线上传来利好。该公司研发的多发性硬化症实验性口服药在两项后期临床试验中取得成功，有望成为该中枢神经系统自身免疫性疾病的新型口服疗法。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>诺华周二表示，试验显示，接受瑞米布替尼(remibrutinib)治疗的患者与接受特立氟胺(teriflunomide)治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。这一成果也进一步强化了BTK抑制剂的市场前景，这类药物旨在抑制疾病中有害的免疫反应。此前，赛诺菲和默克公司的类似药物在后期试验中未能在复发率指标上优于特立氟胺。该药物还可能加剧与罗氏的竞争。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>诺华计划在全球范围内提交瑞米布替尼用于治疗多发性硬化症的上市申请，详细结果将于今年晚些时候在多伦多的一次医学会议上公布。该药物目前在美国和欧洲已获批用于治疗慢性自发性荨麻疹，这是一种以反复发作风团为特征的皮肤病。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>最专业的美股资讯,推荐美股大数据 \u003Ca href=\"https:\u002F\u002FStockwe.com\u002F\">https:\u002F\u002FStockwe.com\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如何识别美股市场异常波动？美国机构主力资金买卖情况，出货和吸筹，使用美股投资网VIP会员，2008年成立于美国硅谷，由前纽约证券交易所分析师Ken创立，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化模型，建立了一个股市数据库 \u003Ca href=\"https:\u002F\u002FStockWe.com\u002F\">https:\u002F\u002FStockWe.com\u002F\u003C\u002Fa> 每天处理千万级股票数据：捕捉期权大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准交易信号第一时间发到您手机APP！\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FC\u002FCAR\u002FCAR.jpg","2026-09-01T14:38:44","2026.09.01","2026\u002F09\u002F01",31147,[22],"CAR","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" rel=\"noopener noreferrer\">\u003Cimg src=\"\u002Fimg\u002Fstockwewebfiles\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[44,47,50,53,56,59,62,65,68],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"AI智能体","\u002FAiAgent",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]